1例惠普尔养障体致肺部感染的药物治疗分析  

Pharmacotherapy Analysis of One Case of Pulmonary Infection Caused by Tropheryma Whipplei

作　　者：徐光辉 杜同心 盛淇 王金平[3] XU Guanghui;DU Tongxin;SHENG Qi;WANG Jinping(Southern University of Science and Technology Hospital,Department of Clinical Pharmacy,Shenzhen 518055,China;Southern University of Science and Technology Hospital,Department of Chest Surgery,Shenzhen 518055,China;Department of Pharmacy,Shenzhen Second People's Hospital,Shenzhen 518035,China)

机构地区：[1]南方科技大学医院临床药学科,广东深圳518055 [2]南方科技大学医院胸外科,广东深圳518055 [3]深圳市第二人民医院药学部,广东深圳518035

出　　处：《中国现代应用药学》2025年第5期766-769,共4页Chinese Journal of Modern Applied Pharmacy

基　　金：国家卫健委医院药学高质量发展研究项目(NIHAYS2317);广东省医院药学研究基金(澳美基金)(2022A07);中国优生优育协会科研项目(2024K040)。

摘　　要：目的提高对肺部感染惠普尔养障体抗感染药物治疗的认识。方法回顾性分析1例惠普尔养障体引起免疫力正常患者肺肿物的临床资料,通过查阅指南和近3年相关文献报道,分析及总结惠普尔养障体致肺部感染的抗感染药物治疗方案。结果患者使用头孢曲松联合复方磺胺甲噁唑抗感染治疗后病情好转,继续复方磺胺甲噁唑序贯治疗,随访结果显示肺肿物明显缩小,治疗有效。结论惠普尔养障体致免疫正常患者肺肿物较罕见,应及时明确病原菌,尽早使用以头孢曲松、复方磺胺甲噁唑为基础的单药或者联合治疗的抗感染方案。OBJECTIVE To enhance understanding of antimicrobial therapy for pulmonary infections caused by Tropheryma whipplei.METHODS The clinical data of one case of lung mass caused by Tropheryma whipplei in an immunocompetent patient were retrospectively analyzed,and the anti-infective drug treatment plan for lung infection caused by Tropheryma whipplei was analyzed and summarized by reviewing the guidelines and the relevant literature reports in the past three years.RESULTS After receiving anti-infective treatment with ceftriaxone combined with cotrimoxazole,the patient's condition improved.The patient continued with sequential therapy using cotrimoxazole.Follow-up results showed a significant reduction in the lung mass,indicating that the treatment was effective.CONCLUSION Lung mass in immunocompetent patients due to Tropheryma whipplei are rare,and the pathogen should be promptly identified and an anti-infective regimen based on ceftriaxone and cotrimoxazole,either as a single agent or in combination,should be used at the earliest possible time.

关 键 词：惠普尔养障体 肺肿物 抗感染治疗 

分 类 号：R969.3[医药卫生—药理学]